When a drugmaker's top product loses patent protection, the dividend usually takes the hit. Four pharma giants are each ...

This week, the companies announced wins across their late-stage Clarity-1 and Clarity-2 studies of once-daily brepocitinib in ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. In a unique challenge to drug makers, the Dutch Pharmaceutical ...

CVS Health is the first major player to end some of its Humira coverage in order to make way for biosimilars. (CVS) This year, CVS Health plans to employ the classic "out with the old, in with the new ...

Pharmaceutical giant AbbVie (ABBV +0.73%) is known for its top-selling drug Humira and its lucrative dividend that yields more than 4% at the current share price. This week Humira, which treats ...

The arthritis drug Humira has been a blockbuster seller for more than two decades. Now, some copycats could end Humira's reign. The blockbuster drug Humira has been one of the world's top sellers for ...

Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter ...

Humira (adalimumab) and Remicade (infliximab) are prescription drugs used to treat certain inflammatory conditions. Humira is given as an injection, while Remicade is given as an infusion. Humira and ...

Humira has been one of the world's top selling drugs for more than two decades. But thanks to some new copycats — including one that is being sold at entrepreneur Mark Cuban's online pharmacy — its ...

AbbVie Inc. (NYSE:ABBV) is delivering strong returns this year, with shares surging by over 23% year-to-date. In comparison, ...